Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Clear all
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

NCT00528996
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BEA 2180 BR, Tiotropium Bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 100 Years
Enrollment
2,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
56
States / cities
Jasper, Alabama • Mobile, Alabama • Berkeley, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia

NCT00673452
View directory record Official record
Conditions
Fibromyalgia
Interventions
duloxetine hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2010 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 2 Interventional

An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee

NCT00211549
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
IDEA-033
Drug
Lead sponsor
IDEA AG
Industry
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
100
States / cities
Birmingham, Alabama • Montgomery, Alabama • Northport, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2009 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

NCT03976349
View directory record Official record
Conditions
Parkinson's Disease
Interventions
BIIB094, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Farmington Hills, Michigan • Cleveland, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Systematic Evaluation of Antiviral Medication in Schizophrenia

NCT00514449
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
Konasale Prasad
Other
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Detroit, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine in Pathologic Skin Picking

NCT01063348
View directory record Official record
Conditions
Pathologic Skin Picking, Neurotic Excoriation, Psychogenic Excoriation, Dermatillomania
Interventions
N-Acetyl Cysteine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1020-CP-001

NCT03179878
View directory record Official record
Conditions
Healthy Volunteer, Urea Cycle Disorder
Interventions
Placebo, SYNB1020
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Not applicable Interventional Results available

Ketone Supplementation in Cystic Fibrosis

NCT04938726
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ketone Monoester
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

NCT05679908
View directory record Official record
Conditions
Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine
Interventions
TNX-1900, Placebo Nasal Spray
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
26
States / cities
Little Rock, Arkansas • Lemon Grove, California • Oceanside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 31, 2026, 1:12 PM EDT
Terminated Phase 3 Interventional

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

NCT04857840
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Firibastat (QGC001) Period 1
Drug
Lead sponsor
Quantum Genomics SA
Industry
Eligibility
18 Years to 99 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 2 Interventional

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

NCT04497168
View directory record Official record
Conditions
Parkinson Disease
Interventions
Citalopram 20mg, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants

NCT03341390
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Aspirin, BMS-986177, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Berry Intake on Metabolic Control and Cognitive Function

NCT03879213
View directory record Official record
Conditions
Healthy
Interventions
Active breakfast, Control breakfast
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
55 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI

NCT00586820
View directory record Official record
Conditions
Myocardial Reperfusion Injury
Interventions
BQ-123, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of L-NAME and Midodrine to Increase MAP

NCT00835224
View directory record Official record
Conditions
Orthostatic Hypotension, Spinal Cord Injury
Interventions
L-NAME, Midodrine, Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)

NCT04370548
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
DARE-BV1clindamycin phosphate vaginal gel, 2%
Drug
Lead sponsor
Daré Bioscience, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Tucson, Arizona • Denver, Colorado • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 31, 2026, 1:12 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of a Black Rice Extract and Anthocyanidin Metabolites on the Synthesis and Release of BDNF in Healthy Subjects

NCT06594848
View directory record Official record
Conditions
Cognition - Other, Depression, Anxiety
Interventions
Black rice extract, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2541546 in Healthy Postmenopausal Women

NCT01742078
View directory record Official record
Conditions
Healthy
Interventions
LY2541546 - IV, LY2541546 - SC, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Evansville, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

NCT01709578
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
56
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

NCT00456885
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance
Interventions
exenatide, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 31, 2026, 1:12 PM EDT
Not yet recruiting Phase 2 Interventional

Allopregnanolone in Chronic Complex Traumatic Brain Injury

NCT04003285
View directory record Official record
Conditions
Traumatic Brain Injury (TBI)
Interventions
Placebo, Allopregnanolone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 62 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 1:12 PM EDT
Terminated Phase 3 Interventional

Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

NCT00741715
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
AVE5530, atorvastatin, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)

NCT02618408
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPN-810 (18 mg), SPN-810 (36 mg), Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
28
States / cities
Rogers, Arkansas • Culver City, California • Glendale, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 31, 2026, 1:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Understanding Effects of Calcium on the Gut-Bone Axis

NCT06383117
View directory record Official record
Conditions
Healthy, Adult, Calcium, Bone Resorption, Endocrine; Obesity
Interventions
Calcium carbonate, Placebo Control
Dietary Supplement
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 31, 2026, 1:12 PM EDT